Condition: Non Small Cell Lung Cancer NSCLC · Sponsor: Mario Negri Institute for Pharmacological Research
Aim of this phase 2 study is to explore the safety and efficacy of thoracic re-irradiation +/- SBRT to oligometastases (\<3) followed after an interval of 2 weeks by durvalumab and ceralasertib for patients with thoracic relapses +/- oligometastases after PACIFIC or PACIFIC-like (concurrent or sequential chemo-radiotherapy followed by maintenance durvalumab) regimens.
This description comes directly from the study's public registry record.
Irene De Simone, Project manager · +39 02 39014661 · irene.desimone@marionegri.it
Always discuss trial participation with your own doctor first.
| ASST degli Spedali Civili di Brescia | Brescia, Italy | Not Yet Recruiting |
| Azienda Ospedaliero Universitaria Careggi | Florence, Italy | Recruiting |
| IRCCS Ospedale Policlinico San Martino, Genova | Genova, Italy | Recruiting |
| ASST Grande Ospedale Metropolitano Niguarda | Milan, Italy | Recruiting |
| Fondazione IRCCS Istituto Nazionale dei Tumori | Milan, Italy | Recruiting |
| Azienda ospedaliera di Padova | Padova, Italy | Not Yet Recruiting |
| Azienda Ospedaliero - Universitaria di Parma | Parma, Italy | Not Yet Recruiting |
| University Hospital of Geneva | Geneva, Switzerland | Not Yet Recruiting |
| University Hospital Zurich | Zurich, Switzerland | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06680050